and Humulin U-500 for diabetes; Jardiance, Mounjaro, and Trulicity for type 2 diabetes; and Zepbound for obesity. Receive News & Ratings for Eli Lilly and Company Daily - Enter your email address ...

The United States Food and Drug Administration says the shortage of Eli Lilly’s Zepbound and Mounjaro drugs has been resolved and that specialty pharmacies and online companies need to stop ...

Eli Lilly (LLY) closed at $795.67 in the latest trading session, marking a -0.08% move from the prior day. The stock's performance was behind the S&P 500's daily gain of 1.1%. Elsewhere ...

Eli Lilly (LLY) stated: “In a win for patients, the judge overseeing Lilly’s International Trade Commission case determined that U.S. Customs and Border Protection should prevent the illicit ...

and Humulin U-500 for diabetes; Jardiance, Mounjaro, and Trulicity for type 2 diabetes; and Zepbound for obesity. Receive News & Ratings for Eli Lilly and Company Daily - Enter your email address ...

This copy is for your personal, non-commercial use only. Distribution and use of this material are governed by our Subscriber Agreement and by copyright law. For non-personal use or to order ...

The Food and Drug Administration approved Eli Lilly's blockbuster weight loss drug Zepbound for treating patients with the most common sleep-related breathing disorder. The weekly injection is now ...

This year's developments in the obesity market have really gone in Eli Lilly’s (NYSE:LLY) favor. Clinical trial results from competitors were largely underwhelming, including this week’s ...